THMO thermogenesis.com: Forward P/S Multiple

ThermoGenesis is recognized as the global benchmark in the field of stem cell cryopreservation. The forward P/S valuation history clearly demonstrates the dynamics of market expectations, while the 0.10 metric confirms the current valuation level. Stable cash flow is driven by the sale of consumables, and management's transformation toward CDMO services creates potential for future revenue growth.

thermogenesis.com - THMO Market Cap to Expected Sales Ratio (period 07/04/2022 - 08/04/2024)

Metric breakdowns and analytics for Cesca Therapeutics (THMO)

- current price and projected stock value:

Stock Price ThermoGenesis Holdings|THMO - Average Forecast Price

- company stock capitalization data:

Market Capitalization Cesca Therapeutics|THMO - Business Value

- issuer book value statistics:

Book Value per Share ThermoGenesis|THMO - Book Valuation of Business|Market Capitalization to Book Value Ratio thermogenesis.com|THMO - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

THMO - Annual Net Income|Future Profit ThermoGenesis|THMO - P/E Multiple|Forward P/E Multiple ThermoGenesis Holdings Inc.|THMO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cesca Therapeutics|THMO - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months ThermoGenesis|THMO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth thermogenesis.com|THMO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year ThermoGenesis

- sales volume and revenue indicators:

THMO - Company Sales Volume|Company Future Sales Volume ThermoGenesis Holdings|THMO - Market Cap to Sales Volume|Forward Price-to-Revenue Multiple Cesca Therapeutics

Summary company analytics:ThermoGenesis Holdings (THMO)

Investors utilize asset filtering based on forward multiples to identify undervalued companies with sustainable growth potential. The forward P/S ratio compares current market capitalization with expected sales volume, which for ThermoGenesis (THMO) allows for an assessment of the business's market value relative to the adoption rates of stem cell processing automation systems, reflecting the scaling efficiency of robotic solutions through the price action on this chart.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|mesalabs.com - Price-to-Projected Revenue Ratio|QSI: Forward Price-to-Revenue Multiple|Forward Price to Sales NNOX (Nano-X Imaging)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908 Devices Corporation (MASS)|Price-to-Projected Revenue Ratio CapsoVision, Inc.|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple RPID (Rapid Micro Biosystems)|Forward P/S Multiple Seer Inc (SEER)|Forward P/S Multiple HYPR (Hyperfine Corp)|Market Cap to Expected Sales Ratio FONAR Corporation Inc (FONR)|DXR - Price-to-Projected Revenue Ratio|Future Price to Revenue MDAI|VivoSim Labs Inc (VIVS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Aclarion Inc|AKYA (Akoya Biosciences Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Talis Biomedical Corp TLIS|Price-to-Projected Revenue Ratio T2 Biosystems, Inc. (TTOO)